H.C. Wainwright resumed coverage on MetaVia with a new price target
$MTVA
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/4/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $12.00 | Buy | H.C. Wainwright |
CAMBRIDGE, Mass., June 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present an update highlighting the company's pipeline of novel obesity and metabolic therapies at the Emerging Growth Conference on Thursday, June 11, 2026 at 3:25 pm ET. After the presentation, MetaVia's management will open the floor for questions. Attendees may submit questions in advance to questions@emerginggrowth.com, or ask questi
48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of PlateauExploratory FibroScan Assessments Demonstrated Early Liver-Related ImprovementsOngoing Phase 1 Part 3a/3b Titration Studies Continue to Evaluate Extended Treatment at Higher-Dose LevelsCAMBRIDGE, Mass., May 27, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual oxyntomodulin (OXM) analog agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), in a late-breaking poster presentation at the European Ass
CAMBRIDGE, Mass., May 20, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the publication of new preclinical research supporting the anti-fibrotic potential of vanoglipel (DA-1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in the peer-reviewed, international journal, Biomolecules & Therapeutics. The paper, entitled, "A Novel Anti-Fibrotic Role of G-Protein-Coupled Receptor 119 in Hepatic Stellate Cells," demonstrated that GPR119 agonists reduced liver fibrosi
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
8-K - MetaVia Inc. (0001638287) (Filer)
8-K - MetaVia Inc. (0001638287) (Filer)
SCHEDULE 13G - MetaVia Inc. (0001638287) (Subject)
4 - MetaVia Inc. (0001638287) (Issuer)
4 - MetaVia Inc. (0001638287) (Issuer)
H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00
CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions